Search
Serine
go.drugbank.com/drugs/DB00133ApprovedInvestigationalNutraceuticalA non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … Nicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent.
Monopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low. … Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion.
Mixtures: NUTRIFLEX PERI IN 2000ML TWIN-FLEX, NUTRIFLEX SPECIAL IN 1000ML TWIN FLEXCategories: Compounds used in a research, industrial, or household settingBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigational[L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]
Ritonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalAmerican Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules.
Mixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOSCategories: Antivirals used in combination for the treatment of HIV infectionsRespiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.
Selenium
go.drugbank.com/drugs/DB11135ApprovedInvestigationalVet approvedSelenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen
Mixtures: Multi II IV Vi Tab, Formula InfCategories: Compounds used in a research, industrial, or household settingSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.